Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors

Philip J. Mease; Jessica A. Walsh; Timothy P Fitzgerald; Soumya D. Chakravarty; Elizabeth Adamson; Bruno Emond; Carmine Rossi; Samuel Schwartzbein; Kana Yokoji; Yuxi Wang; Patrick Lefebvre; Dominic Pilon; Shikha Singla; Joseph F Merola

doi:10.1007/s12325-025-03416-z

November 21, 2025Advances in TherapyOpen Access

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors

View Full Paper

Ask AI

Bookmark

Share

Key Points

Evaluate treatment persistence rates over 24 months for guselkumab versus IL-17A inhibitors in patients with psoriatic arthritis.
Real-world study comparing two treatment groups over 24 months.
Participants included biologic-naïve and biologic-experienced patients.
Utilized treatment persistence as the primary outcome measure.
Greater on-label treatment persistence rates observed with guselkumab at 24 months.
Both biologic-naïve and biologic-experienced subgroups showed similar trends.

Implication

Real-world comparison reveals higher treatment persistence with guselkumab than IL-17A biologics in patients with psoriatic arthritis.

Abstract

This real-world study identified greater on-label treatment persistence rates at 24 months in patients with active PsA initiating guselkumab versus SC IL-17Ai, overall and among biologic-naïve and biologic-experienced subgroups.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mease et al. (2025) studied this question.

synapsesocial.com/papers/6924e3e6c0ce034ddc34ec2d https://doi.org/10.1007/s12325-025-03416-z

View Full Paper

Ask AI

Bookmark

Share

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors

Key Points

Implication

Abstract

Discussion

Cite This Study

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading